Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Medacta Group SA (MOVE.S)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (CHF)	Price Target (CHF)	Rating
2022-02-16	116.40	138.00	Neutral
2022-04-26	104.40	135.00	Buy
2022-07-20	88.80	119.00	Buy
2022-08-01	94.10	117.00	Buy
2022-09-20	91.00	115.00	Buy
2022-11-28	104.40	108.00	Neutral
2023-03-24	97.20	104.00	Neutral
2023-06-23	120.60	120.00	Neutral
2023-10-09	111.20	119.00	Neutral
2023-12-20	129.60	137.00	Buy
2024-03-14	125.40	141.00	Buy

Disclosures

UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.